November 29 - 30, 2018
Radisson Blu Royal Hotel
Nov. 29-30, 2018Radisson Blu Royal HotelBrussels, Belgium
Registration Deadline: Thursday, Nov. 15, 2018 (now open)
Organizing Committee ChairsDenis A. Lacombe, European Organization for Research and Treatment of Cancer (EORTC), Brussels, BelgiumRoberto Salgado, GasthuisZusters Antwerp (GZA), Antwerp, Belgium
Organizing Committee CochairsJonas C. S. Bergh, Karolinska Institute University Hospital, Stockholm, SwedenMichael A. Caligiuri, James Cancer Hospital & Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OhioLyndsay N. Harris, National Institutes of Health, Rockville, MarylandTracy G. Lively, National Cancer Institute, Rockville, MarylandFrancesco Pignatti, The European Medicines Agency (EMA), London, EnglandVictor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
Never before has cancer drug and biomarker development been so complex and required such a diverse range of expertise. Following the success of the IBCD2016 program in Brussels, the EORTC, NCI, EMA, and AACR are once again collaborating on a unique program with the intention of stimulating the dialog between those conducting clinical trials and those working in the laboratory. This unique program will spotlight multi-stakeholder approaches to cancer drug development with new cancer biomarkers. Plenary lectures and panel discussions will include key opinion leaders representing regulators, payers, industry, patients, and academia in order to enhance collaborations needed for developing improved treatments for patients with cancer.